Advertisement

Universal venous thromboembolism policy is effective but may not adequately protect hospitalized cancer patients with larger BMI

  • Anna Xu
  • Hassan SibaiEmail author
  • Eshetu G. Atenafu
  • Kelsey Japs
  • Jack T. Seki
Article
  • 19 Downloads

Abstract

Routine VTE prophylaxis is recommended for hospitalized patients, but its effectiveness and safety in cancer patients is unclear. By observation, larger patients seemed poorly covered by the prophylaxis policy. The effectiveness and safety of VTE prophylaxis policy in the hospitalized patients, their potential risk factors such as BMI were examined. A retrospective chart review was conducted to determine VTE incidences, risk factors for VTE and major bleeding events between 2007 and 2016 on the solid tumor units (STU). Patients were divided into pre-policy (Pre-2012) or post-policy implementation groups (Post-2012). Descriptive statistics were used to evaluate effectiveness and safety of prophylaxis, while propensity score matching (1:3, VTE:Non-VTE) was used to reduce selection bias. The VTE incidence per patient was 1.30% (57/4392) pre-policy and 0.56% (18/3210) post-policy (p value = 0.0013). After propensity score matching, a reduction (32.3%) of VTE cases was observed after policy implementation (OR = 0.677, p = 0.32). BMI was found to be a significant predictor of VTE (OR = 1.094, 95% CI 1.021–1.172, p = 0.011). Between July 2014 and July 2016, 1.7% (19/1091) patients who received anticoagulants had a documented bleeding event. The policy positively impacted VTE events on the STU. A significant predictor of VTE was BMI and patients with high BMI may pose a risk of breaking through standard VTE prophylaxis dosing. There was no reported major bleeding for patients who developed an VTE event despite receiving prophylaxis in either the pre-policy or post-policy phase of the study, although a low incidence of minor bleeding was documented in the post-phase.

Keywords

Anticoagulants Large BMI Quality improvement Risk factors Venous thromboembolism 

Notes

Acknowledgements

Dr. M.K. Krzyzanowska is acknowledged for the review of the manuscript, Jennifer Carter, Nathalie Nguyen, Joseph Samuel, Naoko Sakurai, Andrew Stessman, Helen Thu Vu, Tian, Q. Wang and Maria Zigas are recognized for their help with data abstraction, clinical pharmacists on 17A and 17B in-patient units, the Pharmacy Informatics Department and Decision Support Department at UHN for their assistance with the generation of specified data.

Author contribution

AX participated in data collection and drafted the manuscript. HS participated in data interpretation and edited the manuscript. MKK participated in reviewing the manuscript. EGA participated in study design, statistical analysis, and edited the manuscript. KJ participated in data collection and edited the manuscript. JTS principal investigator and senior author participated in the study design and editing of the manuscript.

References

  1. 1.
    Ratib S, Walker AJ, Card TR, Grainge MJ (2016) Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study. J Hematol Oncol 9:60CrossRefGoogle Scholar
  2. 2.
    Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clin Outcomes Res 5:101–108CrossRefGoogle Scholar
  3. 3.
    Ma KA, Cohen E, Kahn SR (2014) Venous thromboembolism in hospitalized patients: an updated analysis of missed opportunities for thromboprophylaxis at a university-affiliated tertiary care center. Vasc Med 19(5):385–391CrossRefGoogle Scholar
  4. 4.
    Barsam SJ, Patel R, Arya R (2013) Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol 161:764–777CrossRefGoogle Scholar
  5. 5.
    Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH (2012) Prevention of VTE in nonsurgical patients. 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e195S–e226SCrossRefGoogle Scholar
  6. 6.
    Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A (2013) Venous Thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol 31:2189–2204CrossRefGoogle Scholar
  7. 7.
    Cohen AT, Gurwith MMP, Dobromirski M (2012) Thromboprophylaxis in non-surgical cancer patients. Thromb Res 129:S137–S145CrossRefGoogle Scholar
  8. 8.
    Kuderer NM, Lyman GH (2014) Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res 133(Suppl 2):S122–S127CrossRefGoogle Scholar
  9. 9.
    Di Nisio M, Carrier M, Lyman GH, Khorana AA (2014) Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 12:1746–1749CrossRefGoogle Scholar
  10. 10.
    Canada Accreditation (2017) Required Organizational Practices Handbook 2017. Accredit Canada Inc., OttamaGoogle Scholar
  11. 11.
    Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341:793–800CrossRefGoogle Scholar
  12. 12.
    Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879CrossRefGoogle Scholar
  13. 13.
    Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AGG, Egberts JFM, Lensing AWA (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 332(7537):325–329CrossRefGoogle Scholar
  14. 14.
    Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127(1):82.e1–86.e1CrossRefGoogle Scholar
  15. 15.
    Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M (2014) Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol 16(12):1079–1090CrossRefGoogle Scholar
  16. 16.
    Lee A, Brose K (2008) Cancer-associated thrombosis: prevention and treatment. Curr Oncol 15(1):S58–S67PubMedPubMedCentralGoogle Scholar
  17. 17.
    Seki JT, Vather T, Atenafu EG, Kukreti V, Krzyzanowska MK (2014) Bridging efforts to longitudinally improve and evaluate venous thromboembolism prophylaxis uptake in hospitalized cancer patients through interprofessional teamwork (BELIEVE IT): a study by princess margaret cancer centre. Thromb Res 133(1):34–41CrossRefGoogle Scholar
  18. 18.
    Sibai H et al (2016) Anticoagulation prevention in asparaginase-based therapy in acute lymphoblastic leukemia. Curr Oncol 23:e355–e361CrossRefGoogle Scholar
  19. 19.
    Sibai H, Chen R, Liu X, Schimmer AD, Schuh A, Law A, McNamara CJ, Maze D, Yee KWL, Minden MD, Chan SM, Gupta V, Murphy T, Falcone U, Sakurai N, Brandwein JM, Seki J (2018) Anticoagulation prophylaxis with weight-adjusted enoxaparin reduces rates of venous thromboembolism in patients with acute lymphoblastic leukemia receiving asparaginase-based intensification therapy. Blood 132:3974CrossRefGoogle Scholar
  20. 20.
    Princess Margaret Cancer Centre (2019) https://www.uhn.ca/PrincessMargaret. Accessed 30 July 2019
  21. 21.
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 8:2063–2065CrossRefGoogle Scholar
  22. 22.
    Canadian Patient Safety Institute. Accreditation-Canada-recognizes-increasing-compliance-with-VTE-prophylaxis @ www.patientsafetyinstitute.ca. Accessed 30 July 2019
  23. 23.
    Di Nisio M, Candeloro M, Rutjes AWS, Galli V, Tritto M, Porreca E (2018) Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness. Thromb Res 169:44–49CrossRefGoogle Scholar
  24. 24.
    Patell R, Gutierrez A, Rybicki L, Khorana AA (2017) Identifying predictors for bleeding in hospitalized cancer patients: a cohort study. Thromb Res 158:38–43CrossRefGoogle Scholar
  25. 25.
    Freeman A, Horner T, Pendleton RC, Rondina MT (2012) Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 87(7):740–743CrossRefGoogle Scholar
  26. 26.
    He Z, Morrissey H, Ball P (2017) Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients—actual weight-based vs fixed. Crit Rev Oncol Hematol 113:191–194CrossRefGoogle Scholar
  27. 27.
    Pannucci CJ, Hunt MM, Fleming KI, Prazak AM (2017) Weight-based dosing for once-daily enoxaparin cannot provide adequate anticoagulation for venous thromboembolism prophylaxis. Plast Reconstr Surg 140(4):815–822CrossRefGoogle Scholar
  28. 28.
    American Society of Hematology (2018). 9192 @ www.hematology.org. file:///C:/Users/t59nspm/Downloads/ASHSlideSet-MedicalProphylaxis5-17.pdf. Accessed 31 July 2019

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Leslie Dan Faculty of PharmacyUniversity of TorontoTorontoCanada
  2. 2.Division of Medical Oncology and Hematology, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  3. 3.Department of Pharmacy, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  4. 4.Department of Biostatistics, Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada
  5. 5.Drake UniversityDes MoinesUSA

Personalised recommendations